Skip to main content
Premium Trial:

Request an Annual Quote

ProMetic BioSciences Postpones IPO as Business Outlook Brightens

NEW YORK (GenomeWeb News) — Prometic Life Sciences today said an improved financial and competitive landscape has caused it to postpone plans to file an initial public offering for its ProMetic BioSciences subsidiary, a maker of synthetic proteins.
Prometic said the company decided to let its value increase as a private company after certain events buoyed its overall outlook. Among these was the recent approval by European regulators for its P-Capt filter, “favorable changes in the business competitive landscape” for its prion filter, and a string of agreements with pharmaceutical companies, including most recently Novartis.

ProMetic BioSciences develops and manufactures affinity separation materials.


“Because [ProMetic BioSciences] is expected to be cash neutral with projected revenues in excess of $15 million in 2007, it makes more business sense for the benefit of our shareholders not to do an IPO at this time,” said ProMetic CEO Pierre Laurin.
In June, the company closed a private placement with JP Morgan and Third Point worth $9.8 million.
Prometic did not project a new date for an IPO, which would be on the London Stock Exchange.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.